BTIG Reiterates Rating on IRTC $IRTC

Key Points

  • BTIG now rates iRhythm Holdings, Inc. ($IRTC) "buy" with a $185.00 target.
  • The Street's average $IRTC price target is $178.93 (Strong Buy).
  • $IRTC last traded around $113.65.

BTIG reiterated its rating on iRhythm Holdings, Inc. ($IRTC) to a "buy" rating, with a price target of $185.00 in a recent research note.

iRhythm Holdings, Inc. ($IRTC) Stock

Last price$113.65
Market cap$3.73B
Forward P/E108.10
Beta1.28
52-week low$101.75
52-week high$212.00
50-day MA$117.21
200-day MA$151.76
Current ratio5.17
Quick ratio4.79
Debt-to-equity4.52

iRhythm Holdings, Inc. Earnings

EPS (ttm)$-0.85
Revenue (ttm)$787.85M
Revenue growth25.7%
Net margin-3.5%
Return on equity-22.4%
Next earningsJul 30, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$178.93
High target$255.00
Low target$147.00
Analysts covering14

About iRhythm Holdings, Inc.

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

ExchangeNasdaqGS
SectorHealthcare
IndustryMedical Devices
HeadquartersSan Francisco, CA
CEOMr. Quentin S. Blackford
Employees2,400

See Also

This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.